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Abstract
Background: Fesoterodine is an antimuscarinic for the treatment of overactive bladder, a syndrome of urgency,
with or without urgency urinary incontinence (UUI), usually with increased daytime frequency and nocturia. Our
objective was to develop predictive models to describe the dose response of fesoterodine.
Methods: Data from subjects enrolled in double-blind, placebo-controlled phase II and III trials were used for
developing longitudinal dose-response models.
Results: The models predicted that clinically significant and near-maximum treatment effects would be seen
within 3 to 4 weeks after treatment initiation. For a typical patient with 11 micturitions per 24 hours at baseline,
predicted change was -1.2, -1.7, and -2.2 micturitions for placebo and fesoterodine 4 mg and 8 mg, respectively.
For a typical patient with 2 UUI episodes per 24 hours at baseline, predicted change was -1.05, -1.26, and -1.43 UUI
episodes for placebo and fesoterodine 4 mg and 8 mg, respectively. Increase in mean voided volume was
estimated at 9.7 mL for placebo, with an additional 14.2 mL and 28.4 mL for fesoterodine 4 mg and 8 mg,
respectively.
Conclusions: A consistent dose response for fesoterodine was demonstrated for bladder diary endpoints in
subjects with overactive bladder, a result that supports the greater efficacy seen with fesoterodine 8 mg in post
hoc analyses of clinical trial data. The dose-response models can be used to predict outcomes for doses not
studied or for patient subgroups underrepresented in clinical trials.
Trial Registration: The phase III trials used in this analysis have been registered at ClinicalTrials.gov (NCT00220363
and NCT00138723).
Background
Fesoterodine is an antimuscarinic indicated for the
treatment of overactive bladder (OAB) with symptoms
of urge urinary incontinence, urgency, and frequency
[1]. The recommended starting dosage for fesoterodine
is 4 mg once daily, which can be increased to 8 mg
once daily depending on patient response [1]. In 2 pivo-
tal phase III trials, fesoterodine 4 mg and 8 mg were
significantly better than placebo in decreasing the num-
ber of micturitions, urgency episodes, and urgency urin-
ary incontinence (UUI) episodes over 24 hours (P < 0.01
for all comparisons) [2,3]. In a post hoc analysis of
pooled phase III data, improvements in UUI episodes
per 24 hours, mean voided volume (MVV), treatment
response, and continent days per week were significantly
greater with fesoterodine 8 mg compared with fesotero-
dine 4 mg (P < 0.05 for all comparisons) [4]. In a sepa-
rate pooled analysis of the phase III data, fesoterodine
8 mg was significantly better than fesoterodine 4 mg in
decreasing the number of UUI episodes among subjects
with moderate or severe UUI at baseline [5].
The phase III trials evaluated only 2 doses of fesotero-
dine. Although the post hoc analyses suggest a dose-
related increase in efficacy, data from 2 doses alone do
not permit a thorough assessment of the dose-response
relationship of fesoterodine. A pharmacokinetic study
[6] and 2 phase II trials [7,8] included 3 doses of
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fesoterodine (4 mg, 8 mg, and 12 mg), providing addi-
tional data for assessing the dose relationship of phar-
macokinetic exposure and of clinical effects. In the
pharmacokinetic study [6], in which single doses of feso-
terodine were administered to healthy male volunteers,
increases in maximum plasma concentration and area
under the concentration-time curve from time zero to
infinity were dose proportional. In the phase II studies
[7,8], all 3 fesoterodine doses were efficacious in subjects
with OAB, with a linear dose-related improvement seen
in number of micturitions per 24 hours [8].
Although statistically significant differences were seen
favoring the fesoterodine 8-mg dose over the 4-mg dose
on key efficacy endpoints in the phase III trials, a dose-
response relationship in the strictest sense cannot be
established with fewer than 3 dose levels. Therefore,
mathematical models were developed to describe quan-
titative and predictive dose-response relationships of the
effects of fesoterodine. These models utilize individual
subject-level, longitudinal data set from two Phase II
and two Phase III studies. Compared with the traditional
analysis of the end-of-treatment results on study-by-
study basis, this model-based dose-response characteri-
zation is more comprehensive because all available
subject-level data obtained at each study visit after
administration of 3 different dose levels (4, 8, or 12 mg)
from a combined dataset across trials were analyzed.
The value of modeling and simulation in drug devel-
opment is evidenced by its acceptability by drug regula-
tory agencies. As part of the U.S. Food and Drug
Administration (FDA) Modernization Act of 1997, law-
makers stated that “data from one adequate and well-
controlled clinical investigation and confirmatory
evidence (obtained prior to or after such investigation)
are sufficient to establish effectiveness [9].” Modeling
results may be accepted by the FDA to support or con-
firm efficacy [10], as illustrated by the prescribing infor-
mation for gabapentin, for example, which notes that
“pharmacokinetic/pharmacodynamic modeling provided
confirmatory evidence of efficacy across all doses” [11].
In addition to use in drug approval, models can be
used to supplement clinical trial data by predicting out-
comes for scenarios not studied in those trials. Once the
validity and reliability of the model have been estab-
lished, values for dependent variables, such as dose
response, can be calculated for any independent variable,
such as time or drug concentration [9]. Modeling and
simulation can thus be used to predict effects of dose
over time or time for a drug to reach maximum
response in a typical patient, information of value to the
practicing clinician making treatment decisions.
We describe here the use of modeling and simulation to
define dose-response relationships for the clinical effects
of fesoterodine on key bladder diary endpoints and post-
void residual (PVR) urinary volume in patients with OAB.
Methods
A population analysis was conducted using pooled data
from two phase II [7,8] and two phase III [2,3] studies.
The protocol for each study was approved by the appro-
priate ethics committee or institutional review board at
each study site; a list of the institutional review boards
is provided in Appendix I. All subjects provided written
informed consent before study enrollment. Each study
was conducted in compliance with the Declaration of
Helsinki, the International Conference on Harmonisa-
tion Good Clinical Practice guidelines, and local regula-
tions. The phase III trials used in this analysis have been
registered at ClinicalTrials.gov (NCT00220363 and
NCT00138723). The protocols for the phase II trials are
available at ClinicalStudyResults.org (protocol numbers
SP582 [A0221027] and SP668 [A0221029]).
The data set contained pooled response, demographics
and covariates, time, and dosing information. Data were
analyzed using nonlinear mixed-effects modeling (NON-
MEM software system, version VI; GloboMax LLC, Elli-
cott City, Maryland). Individual estimates of parameters
were obtained using POSTHOC, an empirical Bayes
estimation method. The random effect models suffi-
ciently described the error distributions. In the current
modeling and simulation analysis, the developed models
were evaluated for goodness of fit and then subjected to
posterior predictive check (PPC) model evaluation.
Longitudinal modeling was incorporated to estimate
the time when peak effects would be expected after
treatment initiation. Patient demographics, such as age,
sex, and baseline OAB symptoms, were evaluated as
covariates of treatment response. Model simulations
were used to describe expected response in patient sub-
groups of interest, for instance, by age and sex.
Population Model Development
Assessment of model adequacy and decisions about
increasing model complexity were driven by the data
and guided by goodness-of-fit criteria, including visual
inspection of diagnostic scatter plots (eg, observed ver-
sus predicted concentration, residual/weighted residual
versus predicted concentration or time).
Data Assembly
Data from 2514 subjects given placebo or fesoterodine
4 mg, 8 mg, or 12 mg in 2 phase II [7,8] and 2 phase III
[2,3] double-blind 8- or 12-week trials were used to
develop the dose-response models. The number of
patients in each study from whom data were used is
shown in Table 1. Data from a tolterodine group
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included in one of the phase III trials [3] were not used
in model development.
Exploratory data analyses were performed for each
endpoint. Dose-response models were established using
clinical trial data for fesoterodine 4 mg, 8 mg, and
12 mg, but efficacy results are presented only for the
FDA-approved doses of 4 mg and 8 mg. While the
12-mg dose is not an approved dose, the addition of
data from a total of 225 patients who received the
12-mg dose (n = 225) in Phase 2 trials and provided a
total 3 dose levels to strengthen confidence in the shape
of the dose-response relationship.
Efficacy and Safety Endpoints
The 3 efficacy endpoints used in the models were num-
ber of micturitions per 24 hours, number of UUI epi-
sodes per 24 hours, and MVV per micturition. For each
of these endpoints, linear and nonlinear models were
evaluated to describe the expected number of micturi-
tions, number of UUI episodes, and MVV over time for
a patient treated with fesoterodine, taking into account
baseline values, onset of drug and placebo effect, and
treatment effect. Micturition and UUI counts follow the
Poisson distribution, which is a discrete probability dis-
tribution that expresses the probability of a number of
events occurring in a fixed period of time if these events
occur with a known average rate and independently of
the time since the last event. In general, count data are
best described by the Poisson distribution and have
been used previously to model UUI episodes [12].
Typical anticholinergic effects like dry mouth and con-
stipation were generally of mild to moderate severity;
any dose-relationship of adverse events and associated
discontinuation rates was easily apparent from their
descriptive summaries, and further exploration of the
tolerability data did not reveal any significant patient
covariates. Therefore, these adverse events were not
considered for model-based analysis. Because post void
residual urine volume (PVR) can be of potential safety
concern, it was selected to fully understand the dose-
response relationship and patient covariates that may
influence the effect of fesoterodine treatment on PVR.
Given the considerable variability in subject data from
the clinical trials with regard to PVR, logistic regression
equations were developed to model the probability that
PVR would exceed 100 mL in a patient treated with fes-
oterodine at any time point, rather than modeling
changes in PVR over time using longitudinal data. The
100-mL threshold was selected because subjects with a
baseline PVR >100 mL were excluded from the phase II
and III trials; setting a higher threshold would result in
a low number of subjects above the threshold. The PVR
model assessed the following covariates as potential pre-
dictors of effect: number of micturitions and UUI epi-
sodes at baseline; subject age, sex, and body mass index;
and baseline laboratory values.
Model Implementation and Performance Check
Base models tested were both linear and nonlinear with
respect to dose; the treatment effect over time was mod-
eled as either additive or proportional to baseline values.
The final model evaluations included comparisons of
the Objective Function value between hierarchical mod-
els. The statistical significance is considered when there
is a decrease in Objective Function corresponding to a
chi-square distribution with a = 0.01 and degrees of
freedom equal to the difference in the number of esti-
mated parameters between any two models was used as
the criteria for final model selection. Estimates for phar-
macokinetic, pharmacodynamic, and covariate effects
were considered fixed; intersubject and intrasubject vari-
ables were random effects. A step-wise selection of cov-
ariates was followed to select the significant covariates.
The log-likelihood ratio test was used to compare the
base model without any covariates to the model with an
added or deleted covariate. When addition of a covariate
results in a p-value less than 0.01, the covariate is signif-
icant. The addition of covariates is followed by step-wise
deletion of covariates; except, the criteria for deletion if
the change in p-value is not significant (p = 0.001). The
process is repeated until no further covariate is deleted
from the model.
When alternative models for the dose effect on PVR
were tested, the model with the minimum Akaike infor-
mation criterion was the square root model, but this
model was only marginally better than the linear model
Table 1 Number of subjects by study and dose
Placebo Fesoterodine 4 mg Fesoterodine 8 mg Fesoterodine 12 mg Total
Phase II
Cole, 2004 [7] 183 186 172 186 727
Nitti et al, 2006 [8] 43 44 47 39 173
Phase III
Chapple et al, 2007 [3] 277 263 276 0 816
Nitti et al, 2007 [2] 265 266 267 0 798
Total 768 759 762 225 2514
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with similar parameter estimates. Therefore, the linear
model was kept as the base model, and a logit scale was
used for linear effects of dose.
Model performance was assessed using a simulation-
based PPC in which the models and the study design
were used to generate statistics of observed responses of
1000 simulated trial replicates, taking into account
model uncertainty. The model and variables derived
from the observed data set should produce simulated
data similar to the original observed data without bias.
The PPC provides information about the performance
of random effects estimates, whereas a typical diagnostic
scatter plot is primarily informative for fixed effects
estimates.
The PPC was used to validate model performance by
confirming that observed responses were within the pos-
terior distribution of responses from simulated trials.
Parameters in the validated model were then used to
predict treatment effects for fesoterodine and placebo.
The models used for each variable are shown in Addi-
tional file 1.
Results
The structural parameters of the models were well esti-
mated, with coefficients of variation (a measure of the
precision of the estimates obtained) within 15% to 20%
for each efficacy endpoint and within 35% for PVR. The
PPC results indicated good model performance in simu-
lating the longitudinal data and the end-of-treatment
change from baseline after treatment with fesoterodine
versus placebo. The treatment-effect estimates based on
the final model parameters are summarized in Table 2.
Micturitions
Data from 2310 subjects met criteria for inclusion in the
micturition model. The exploratory data analysis of
pooled clinical trial data indicated that the number of
micturitions in subjects given fesoterodine decreased
over time in a dose-dependent manner. The PPC for the
micturition model demonstrating change from baseline
over time is shown in Figure 1. For a typical patient
with 11 micturitions per 24 hours at baseline treated for
12 weeks, the model predicted that the change from
baseline in number of micturitions would be greater
with fesoterodine 4 mg and 8 mg than with placebo
(Table 2). Peak response in number of micturitions was
predicted to occur within approximately 27 days, with
response plateauing after 60 days.
Urgency Urinary Incontinence
Data from 2505 subjects met criteria for inclusion in the
UUI model. In the exploratory data analysis, the number
of UUI episodes decreased over time with each fesotero-
dine dose. The PPC indicated that the model performed
well in simulating the change in UUI episodes from
baseline over time (Figure 2). For a typical patient with
2 UUI episodes per 24 hours at baseline, the predicted
change from baseline after 12 weeks of treatment was
greater with fesoterodine 4 mg and 8 mg than with pla-
cebo (Table 2). No plateau in response to treatment was
seen, with the number of UUI episodes still decreasing
at up to 80 days.
Mean Voided Volume
Data from 2502 subjects met criteria for inclusion in the
MVV model. The PPC showed that the model per-
formed well in simulating change in MVV from baseline
over time (Figure 3). The model predicted that, for a
typical patient, the effect on MVV of 12 weeks of treat-
ment was an estimated increase of 9.7 mL for placebo,
with an additional increase of 14.2 mL and 28.4 mL for
fesoterodine 4 mg and 8 mg, respectively (Table 2).
Peak treatment effect on MVV was predicted to be
achieved after approximately 18 days, with response
over time plateauing after that.
Postvoid Residual Volume
Data from 2385 subjects met criteria for inclusion in the
final model for PVR. Overall, 161 of the 2385 subjects
(6.8%) exceeded a PVR threshold of 100 mL at any
point in time, 57 (2.4%) exceeded a threshold of 150
mL, and 11 (0.5%) exceeded a threshold of 200 mL. In
the exploratory data analysis, PVR in general was low at
baseline, ranging from 0 to 99 mL (PVR >100 mL was
an exclusion criterion in the clinical trials); at last visit,
PVR ranged from 0 to 404 mL. No pattern was seen in
the longitudinal profile for changes in PVR, even among
subjects in whom PVR reached high values at some
point during the trial. The exploratory data analysis
indicated that the percentage of subjects in whom PVR
>100 mL was higher among men and older subjects.
In the PVR model, baseline PVR level, followed by
drug dose, was the most important covariate for the
probability that a patient treated for 12 weeks would
develop PVR >100 mL. The PPC results indicated that
the PVR model performed well in simulating the
Table 2 Predicted change from baseline in bladder diary








UUI episodes per 24
hours
-1.1 -1.3 -1.4
MVV, mL 9.7 14.2* 28.4*
MVV = mean voided volume; UUI = urgency urinary incontinence.
*In addition to increase seen with placebo.
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relationship between drug dose and probability that PVR
would exceed 100 mL. When the PPC results were
modeled by subjects’ sex and age, dose dependence of
the probability of PVR >100 mL was apparent in men
and in older patients (aged >70 years), but there was
little effect in women or patients aged ≤70 years
(Figure 4).
Discussion
The principal goal of our work was to assess the dose-
response relationship for fesoterodine, which was not
possible using data from the phase III clinical trials, in
which only 2 fesoterodine doses were administered. To
establish a reliable dose-response relationship, data from
more than 2 doses are needed for modeling purposes.
By including in our models data from the 2 phase III
trials and 2 phase II studies, in which 3 doses of fesoter-
odine were used, the dose response could be estimated.
The 12-mg dose data, along with data from the
approved 4-mg and 8-mg doses, were used to anchor
the models, particularly in evaluating nonlinear models,
and to establish the appropriateness of linear models.
This model-based approach for defining the dose
response allowed a comprehensive evaluation of indivi-
dual subject-level data collected at each visit across
4 trials encompassing placebo and fesoterodine doses of
4, 8, and 12 mg.
The final models predicted a linear dose-response
relationship for fesoterodine with regard to number of
micturitions, number of UUI episodes, and increase in
MVV and a nonlinear pattern for treatment response
over time. The values reported in table 2 represent the
final model parameter estimates. The final model eva-
luations included Stepwise forward or backward com-
parisons. The selection is based on the likelihood ratio
test, across multiple models, each expressing different
covariate-parameter combinations [13]. The statistical
significance is considered when there is a decrease in
likelihood corresponding to a chi-square distribution
with a = 0.01 and degrees of freedom equal to the dif-
ference in the number of estimated parameters between
any two models. These findings are consistent with the
Figure 1 Posterior predictive check for change from baseline in number of micturitions after taking placebo or fesoterodine 4 mg, 8
mg, or 12 mg.
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results from post hoc analyses of the phase III data, in
which the fesoterodine 8-mg dose was significantly
more effective than the 4-mg dose for several bladder
diary variables, including number of UUI episodes [4,5]
The PPC for each efficacy endpoint indicated good
model performance, with the distribution of the median
predicted values centered on the observed change from
baseline, indicating unbiased predictions [14]. Overall,
the models predicted that clinically significant effects
would be seen within 3 to 4 weeks after initiation of
treatment. Of note, predicted peak response in number
of micturitions and MVV was seen within about 3 to 4
weeks after treatment was started, with response pla-
teauing thereafter, but number of UUI episodes contin-
ued to decrease even after 11 weeks of treatment.
The predicted change in number of micturitions is
consistent with results from the 2 phase III trials. In
those studies, the least squares mean change in micturi-
tions per 24 hours was -1.8 and -1.6 for fesoterodine
4 mg and -1.9 and -2.1 for fesoterodine 8 mg [2,3].
Modeling predicted a decrease of -1.7 and -2.2 with fes-
oterodine 4 mg and 8 mg, respectively. For UUI epi-
sodes, the model predictions were slightly lower than
those obtained in phase III trials. The least squares
mean change from baseline in UUI episodes per
24 hours in the clinical trials was -2.0 and -1.7 for feso-
terodine 4 mg and -2.2 and -2.3 for fesoterodine 8 mg
[2,3], compared with predictions of -1.3 and -1.4 for
fesoterodine 4 mg and 8 mg in the models. For MVV,
predicted results (increase from baseline of 23.9 mL and
38.1 mL for fesoterodine 4 mg and 8 mg, respectively)
showed some similarity to those obtained in the phase
III trials, in which the least squares mean change for
MVV was 27.2 and 16.5 mL for fesoterodine 4 mg and
33.6 mL in both studies for fesoterodine 8 mg [2,3].
A dose-dependent increase in PVR >100 mL was
apparent in men and patients aged >70 years but not in
women or patients aged ≤70 years. The longitudinal
profile of PVR did not show any relevant pattern, even
in subjects who reached PVR >100 mL at some point
Figure 2 Posterior predictive check for change from baseline in number of urgency urinary incontinence (UUI) episodes after taking
placebo or fesoterodine 4 mg, 8 mg, or 12 mg.
Cardozo et al. BMC Urology 2010, 10:14
http://www.biomedcentral.com/1471-2490/10/14
Page 6 of 11
during treatment. The risk of acute urinary retention
may be related to increases in PVR. However, there is
currently no threshold of PVR volume or relative
increase in PVR that has been established as being asso-
ciated with increased risk of AUR; 100 mL is a very con-
servative threshold, the clinical significance of which is
unclear [15,16]. The proportion of patients with PVR
>150 mL was 2.4%, and only 0.5% of patients exceeded
the PVR threshold of >200 mL. For men starting treat-
ment with an antimuscarinic, the risk of acute urinary
retention, appears to be greatest during the first 30 days
of treatment and particularly in the first 2 weeks [17].
Consequently, as with other antimuscarinics, it may be
prudent to monitor PVR in older men starting treat-
ment with fesoterodine, at least during the first month
of treatment.
The underlying clinical data for modeling fesoterodine
response were derived from trials in which subjects
were randomly assigned to a fixed-dose group, which
differs from clinical practice where patients can modify
their dosing regimen to target a desired level of treat-
ment response. While it might be perceived as a limita-
tion of these analyses of fixed-dose studies as flexible-
dose studies may be more clinically relevant, the latter
are not suitable to elicit a pharmacologic or clinical
dose response, which is best illustrated through fixed-
dose studies. A broader dose range could not be
explored in these models as the clinical experience with
fesoterodine, based on its benefit-risk assessment, was
limited to the 4-12 mg dose range evaluated in Phase II
trials and 4-8 mg in Phase III trials. The fewer numbers
of subjects at the 12 mg dose level are reflected in the
somewhat wider confidence interval widths around the
model-predicted response at that dose, particularly for
micturitions and PVR. Finally, the modeling included
data from patients with demography typically repre-
sented in OAB clinical trials (about 80% females and
average age 65 yrs); nevertheless the covariate analysis
in these models helps predict the population under-
represented in the trials.
Figure 3 Posterior predictive check for change from baseline in mean voided volume (MVV) after taking placebo or fesoterodine 4
mg, 8 mg, or 12 mg.
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Evaluating the dose-response relationship of new
drugs is necessary to establish which doses will provide
the greatest efficacy with the fewest adverse effects. If
the dose-response relationship is linear, then each
increase in dose yields an increase in effect, whether
positive (improved efficacy) or negative (worsened toler-
ability or safety), or both. Dose-response data can be
obtained from clinical trials, but inclusion of a large
number of endpoints, such as multiple dosing regimens,
is not appropriate for trial subjects and may not be fea-
sible for investigators or sponsors. Model-based drug
development provides a supplemental means of asses-
sing the risks and benefits of increasing drug dosage.
Although development of valid models can be complex
and time consuming, modeling offers a reasonable and
valuable approach to predicting the effects of increasing
dose on clinical endpoints, information that may be use-
ful in clinical practice.
In addition to supplementing or confirming data
obtained in clinical trials, models can be used to simu-
late outcomes using variables not included in preclinical
or clinical studies [14]. These simulations can be used
to predict the probability of an event and to evaluate
the effects of covariates, such as subject age and sex; for
instance, in our work, models were used to assess the
probability of increased PVR in subgroups specifically
stratified by age and sex.
Conclusions
The results from our models demonstrate the value of
modeling for increased understanding of the benefits
and risks of modifying the dose of fesoterodine in treat-
ing patients with OAB. The modeling and simulation
results quantitatively demonstrate a dose-response rela-
tionship for the effect of fesoterodine on key clinical
OAB endpoints.
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